|
[1]
|
Y. Seino, A. Ogawa, T .Yamashita, M. Fukushima, K. Ogata, H. Fukumoto, T. Takano, “Application of NT- proBNP and BNP measurements in cardiac care: A more discerning marker for the detection and evaluation of heart failure”, Eur. J. Heart Fail., Vol. 6, No. 3, 2004, pp 295-300.
|
|
[2]
|
N. van der Burg-de Graauw, C.M Cobbaert , C .J Middelhoff , T.A Bantje, .van Guldener, “The additive value of N-terminal pro-B-type natriuretic peptide testing at the emergency department in patients with acute dyspnea”, Eur. J. Intern. Med., Vol. 20, No. 3, 2009, pp 301-6.
|
|
[3]
|
P.R Fox, M.A Oyama, C. Reynolds, J.E Rush, T.C Defrancesco, B.W Keene, C.E Atkins, K.A Macdonald , K. ESchober , J.D Bonagura , R.L Stepien , H.B Kellihan, T.P Nguyenba, L.B Lehmkuhl, B.K Lefbom, N.S Moise , D.F Hogan, “Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats”, J Vet Cardiol., Vol. 11, Suppl 1, 2009, pp S51-61
|
|
[4]
|
L. Lorgis, M. Zeller, G. Dentan, P. Sicard, P. Buffet , I. L’Huillier, J. C. Beer, M. Vincent-Martin, H. Makki, P .Gambert, Y. Cottin, “RICO Survey Working Group: Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study”, BMJ, Vol. 6, No.338, 2009, pp b1605.
|
|
[5]
|
M. Heringlake, T. Kox, J. Poeling, S. Klaus, T. Hanke, N. Franz, F. Eberhardt, H. Heinze, F. P. Armbruster, L. Bahlmann, “The effects of physical exercise on plasma levels of relaxin, NTproANP, and NTproBNP in patients with ischemic heart disease”, Eur. J. Med. Res., Vol. 14, No. 3, 2009, pp 106-12.
|
|
[6]
|
O. Bruder, C. Jensen, M. Jochims, M. Farazandeh, J. Barkhausen, T. Schlosser, G.V Sabin, P. Hunold, “Relation of B-type natriuretic peptide (BNP) and infarct size as assessed by contrast-enhanced MRI”, Int. J. Cardiol., Vol. 24,No. 144;1 ,2009, pp 53-8.
|
|
[7]
|
S. Garcia, M. S Akbar, S.SAli , F. Kamdar, M.Y Tsai, D.A Duprez, “N-terminal pro B-type natriuretic peptide predicts mortality in patients with left ventricular hypertrophy”, Int J Cardiol., Vol.143, No. 3, 2009, pp 349-52.
|
|
[8]
|
J. Alpert, K. Thygesen, E. Antman, J.P Bassand, “Myocardial infarction redefined: A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction”, J Am Coll Cardiol., Vol.36, 2000, pp 959-969.
|
|
[9]
|
E. Braunwald, E .Antman, J. Beasley, R.M Califf, M.D Cheitlin, J.S Hochman, R.H Jones, D .Kereiakes, et al., “ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)”, J Am Coll Cardiol., Vol. 36, 2000, pp 970-1062
|
|
[10]
|
D .Sahn, A. DeMaria, J. Kisslo, et al., “Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements”, Circulation,Vol. 58, 1978, pp 1072-1083.
|
|
[11]
|
B. Haastrup, S. Gill, S. Kristensen, et al., “Biochemical markers of ischemia for the early identification of acute myocardial infarction without St segment elevation”, Cardiology, Vol. 94, 2000, pp 254-261.
|
|
[12]
|
Y. Seino, K. Ogata, T .Takano, et al., “Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: Comparison with rapid troponin T and myoglobin tests”, Am. J. Med., Vol. 115, 2003, pp 185-190.
|
|
[13]
|
K .Bibbins-Domingo, M .Ansari, N.B. Schiller, B. Massie, M. A Whooley, “B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study”, Circulation, Vol. 108, No. 24, 2003, pp 2987-92.
|
|
[14]
|
M. Weber, T. Dill, R. Arnold, M. Rau, O. Ekinci , K.D .Müller, A. Berkovitsch,V. Mitrovic, C. Hamm , “N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris”, Am. Heart J.,Vol. 148, No. 4, 2004, pp 612-20.
|
|
[15]
|
J .Goetze, C. Christoffersen, M .Perko, H. Arendrup, J.F. Rehfeld, J. Kastrup, L. B. Nielsen, “Increased cardiac BNP expression associated with myocardial ischemia”, Faseb J., Vol. 17, No. 9, 2003, pp 1105-7.
|
|
[16]
|
G.F Baxter, “Natriuretic peptides and myocardial ischaemia”, Basic Res. Cardiol., Vol. 99, 2004, pp 90-3.
|
|
[17]
|
Y. Rautureau and G.F Baxter, “Acute actions of natriuretic peptides in coronary vasculature and ischaemic myocardium”, Curr. Pharm. Des., Vol. 10, No. 20, 2004, pp 2477-82.
|
|
[18]
|
J. Januzzi, A. Chen-Tournoux, G. Moe, “Amino-Terminal Pro–B-Type Natriuretic Peptide Testing for the Diagnosis or Exclusion of Heart Failure in Patients with Acute Symptoms” Am. J. Cardiol., Vol. 101, [suppl], 2008, pp 29A–38A.
|
|
[19]
|
A. Ogawa, Y. Seino, T. Yamashita , K. Ogata , T. Takano, “Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome”, Circ. J., Vol. 70, No. 11, 2006, pp 1372-8.
|
|
[20]
|
A. Tu?cu, O. Y?ld?r?mtürk, S. Aytekin. The diagnostic value of N-terminal B-type natriuretic peptide in diastolic heart failure: comparison with echocardio-graphic findings. Turk. Kardiyol. Dern. Ars., Vol. 37, No. 2, 2009, pp 112-121.
|
|
[21]
|
T. Omland, J .de Lemos, D .Morrow, et al., “Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes”, Am. J. Cardiol.,Vol. 89, 2002, pp 463-465.
|
|
[22]
|
T. Omland, A. Persson, L. Ng, et al., “N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes”, Circulation, Vol. 106, 2002, pp 2913-2918.
|